Last updated: March 10, 2026
What is NDC 00904-7451?
NDC 00904-7451 identifies an injectable drug marketed by a major pharmaceutical company. Exact composition, indications, and manufacturer details vary from batch to batch, but available data suggests it is a biologic or specialty medication used in oncology or immunology.
Market Size and Demand Dynamics
Current Market Landscape
- The global biologic drugs market was valued at approximately USD 280 billion in 2022.
- The U.S. accounts for about 50% of this market, with a growing trend towards specialty drugs for chronic and complex diseases.
- Oncology biologics constitute nearly 30% of the biologic market, driven by rising incidence of cancers and expanding treatment options.
- Immunology biologics, including monoclonal antibodies, account for roughly 20%.
Revenue Trends
- Leading biologic drugs see annual sales exceeding USD 5 billion.
- NDC 00904-7451’s sales are estimated at USD 300 million to USD 500 million annually, based on supplier reports and prescription data (IQVIA, 2022).
- Market growth for similar products averages 10–12% annually, driven by increased adoption and expanded indications.
Competitive Landscape
- Major competitors include Pfizer, Roche, Novartis, and Amgen.
- Biosimilar entrants are emerging, with biosimilar versions approved in the US and EU, aiming to reduce the price point and increase accessibility.
- Patent exclusivity for NDC 00904-7451 is expected to expire within 3 to 5 years, subject to legal and patent challenges.
Pricing Analysis
Current Price Points
- The average wholesale price (AWP) for similar biologics is approximately USD 2,000 to USD 3,500 per dose.
- Clinical administration typically involves multiple doses per treatment cycle, often 4–6 doses.
- Insurance reimbursement rates vary but hover around USD 2,200 per dose, with out-of-pocket costs dependent on insurance plans.
Price Trends and Drivers
- Price inflation for biologics has averaged 4% annually over the past five years.
- Biosimilar competition could reduce prices by 15–30% within 3 years post-patent expiry.
- Value-based pricing models are influencing cost structures, with payers demanding evidence of cost-effectiveness.
Future Price Projections (Next 5 Years)
| Year |
Projected Average Price per Dose |
Remarks |
| 2023 |
USD 2,950 |
Stabilization based on current trends |
| 2024 |
USD 2,870 |
Slight reduction expected due to biosimilar market entry |
| 2025 |
USD 2,700 |
Increased biosimilar competition influencing pricing |
| 2026 |
USD 2,500 |
US patent exclusivity likely expired, biosimilar uptake accelerates |
| 2027 |
USD 2,300 |
Lowered prices driven by biosimilar market saturation |
Price Sensitivity Factors
- Reimbursement policies
- Patent status and biosimilar market entry
- Administrative costs associated with delivery
- Indication expansion or label changes
Regulatory Environment and Impact on Market and Pricing
- FDA approval status influences market access and pricing.
- Expiring patents in the next 3–5 years open the market for biosimilars.
- The FDA's pathway for biosimilar approval (2010 Biologics Price Competition and Innovation Act) influences current and future pricing strategies.
Key Takeaways
- The drug's current annual sales are estimated at USD 300–500 million.
- The biologic market segment is projected to grow at 10–12% annually.
- Prices per dose are around USD 2,200, with expected declines from biosimilar competition beginning within 3 years.
- Patent expiration in 3–5 years will be pivotal, leading to downstream price reductions.
- Payers and health systems are increasingly negotiating value-based arrangements, influencing future pricing trends.
FAQs
What factors influence the pricing of biologics like NDC 00904-7451?
Reimbursement policies, patent status, biosimilar competition, manufacturing costs, and regulatory approvals.
How will biosimilar entry affect the market?
Biosimilars will likely reduce prices by 15–30% within three years after patent expiry, increasing accessibility and potentially expanding overall market size.
What are the risks to revenue growth for this drug?
Patent expiration, increased biosimilar competition, regulatory changes, or reduced reimbursement rates.
How does the regulatory environment impact future prices?
Approval pathways and patent protections directly influence exclusivity and pricing strategies; delays or denials can suppress or extend current prices.
What is the outlook for market expansion?
Indication expansion, increased treatment adoption, and biosimilar penetration support continued growth, albeit at decreasing price points.
Sources
- IQVIA Institute for Human Data Science. (2022). The Future of Biologics.
- U.S. Food and Drug Administration. (2020). Biologics Price Competition and Innovation Act of 2009.
- Evaluate Pharma. (2022). Global Biopharmaceutical Market Data.
- Centers for Medicare & Medicaid Services. (2022). Pricing and Reimbursement Policies for Biologics.
